Human Tissue Engineering Company Prellis Biologics Raises $8.7 Million Series A Round; Announces First Animal Transplant of Its 3D-Printed Tissue
Summary
SAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics today announced that Khosla Ventures has led an $8.7 Series A investment in the company. “We had been using grow-your-own spheroid techniques, which required intricate setups and were inconsistent in size and morphology, complicating downstream analysis,” said Maria Soloveychik, PhD, CEO of SyntheX. The setup is quick and consistent, and the handling is straightforward.” Prellis’ Vascular Tissue Blanks reduce time to drug screening in 3D organoids by an estimated 90% relative to other 3D cell culture technologies. Ultimately, Prellis Biologics has its sights set firmly on human organ transplantation and expects to initiate its first large animal studies before the end of the year. They are surrounded by fine capillary beds that are known to contribute to the structural integrity and engraftment of arteries after the surgical procedure.” More information on Prellis Biologics can be found here.